莫西沙星与头孢哌酮舒巴坦治疗早发性卒中相关性肺炎的临床研究

Efficacy of moxifloxacin and cefoperazone sulbactam on curing early-onset stroke associated pneumonia

目的评价莫西沙星和头孢哌酮舒巴坦治疗早发性卒中相关性肺炎(early-onset stroke associated pneumonia,EOP)临床疗效及细菌学疗效。方法 101例早发性卒中相关性肺炎患者随机分为莫西沙星治疗组和头孢哌酮舒巴坦治疗组,观察两组临床疗效、细菌清除率及多重耐药菌检出情况。结果莫西沙星治疗组和头孢哌酮舒巴坦治疗组临床有效率、细菌清除率分别为76.47%vs 80.00%和80.39%vs 84.21%;两组临床有效率和细菌清除率差异无统计学意义(χ2=0.182,P=0.075vsχ2=1.235,P=1.068);莫西沙星治疗组共检出鲍曼不动杆菌24株,头孢哌酮舒巴坦治疗组36株,两者比较差异有统计学意义(χ2=7.136,P=0.036)。结论莫西沙星治疗EOP在临床疗效和清除率方面与头孢哌酮舒巴坦相当,且其耐药鲍曼不动杆菌产生和耐药性低于后者,可以作为治疗EOP的安全、有效的首选药物之一。

Objective To evaluate the effectiveness and safety of moxifloxacin and cefoperazone sulbactam when they were used in the treatment of early-onset stroke associated pneumonia（EOP）.Methods 102 cases undergoing early-onset stroke associated pneumonia between April 2010 and April 2015 were randomly divided into moxifloxacin group and cefoperazone sulbactam treatment group,respectively.The clinical efficacy,the bacterial clearance rate and the detection rate of bauman acinetobacter strains were compared between two groups.Results No statistical differences were observed on the rates of clinical effectiveness and bacterial clearance between moxifloxacin group and cefoperazone sulbactam treatment group,（76.47%vs 80.00% and 80.39% VS 84.21% respectively;χ2=0.182,P=0.075 andχ2=1.235,P=1.068）.The bauman acinetobacter strains was detected to be 24 and 36 respectively in the moxifloxacin group and cefoperazone sulbactam treatment group,the difference between two groups was statistically significant（χ2=7.136,P=0.036）.Conclusion moxifloxacin is a safe and efficient antibiotic drug for the treatment of EOP,and it should also be the better choice for the treatment of patients with EOP.